New York, May 24, 2026, 09:04 (ET)
Ocugen Inc. goes into the Monday market holiday stuck around $1.34. Trading was muted for the biotech stock on Friday ahead of the Memorial Day break, with shares showing little movement.
Nasdaq traders are off Monday, May 25, for Memorial Day. That means Tuesday is when investors can trade Ocugen shares after last week’s moves and look ahead to the company’s upcoming ophthalmology events.
Ocugen shares ended Friday at $1.34. Volume hit 3.9 million shares. The stock traded from $1.33 to $1.38 during the day. Market cap last quoted around $439 million.
Choppy trading all week for Ocugen, with shares dropping to $1.30 Tuesday before bouncing to $1.36 Wednesday. By Friday’s close, the stock landed back at its Monday finish, according to the company’s historical price data.
That trailed the main indexes. U.S. stocks closed higher Friday. The S&P 500 gained 0.4%, the Nasdaq Composite rose 0.2%, and the Russell 2000 added 0.9%. For the week, those moved up 0.9%, 0.5%, and 2.7%.
Ocugen’s most recent update to the market is the May 14 close of a $130 million 6.75% convertible senior notes offering due 2034. The convertible notes can become equity or be repaid, which may boost cash but could also dilute shareholders.
Ocugen, Inc. said it raised about $112.6 million in net proceeds from its note sale, with roughly $32.7 million used to pay down its Avenue Capital loan. The rest is earmarked for general corporate purposes. CEO Shankar Musunuri said the deal shows “strong momentum” in Ocugen’s “late-stage pipeline.” Ocugen, Inc.
Ocugen’s May 7 filing said the notes first convert at around $2.68 a share. That’s a 45% premium to where the stock closed on May 4, at $1.85. The company limited stock tied to conversion at 67.6 million shares until it gets shareholder approval, according to the filing.
Ocugen, Inc. will present at the Stifel 2026 Virtual Ophthalmology Forum on Tuesday, the company said. No new clinical data is expected at the event. This is the only investor-facing event on the schedule after the holiday.
Ocugen’s main push is still its eye-disease pipeline. The company said earlier this month it finished enrolling patients in two late-stage programs. It’s now aiming for its first Biologics License Application for retinitis pigmentosa, a rare genetic eye disorder. CEO Musunuri said they have “completed enrollment of two” late-stage programs and have “adequate cash runway.” Ocugen, Inc.
Pressure is already building in geographic atrophy, the advanced dry AMD type that can cause major vision loss. Apellis’s Syfovre and Astellas’s Izervay are both on the U.S. market; Ocugen takes a different shot with OCU410, aiming for a modifier gene therapy instead of the usual repeat-injection complement drug.
But the risk here is obvious. Ocugen is still losing money, burned through $21.8 million in operating cash in Q1, and cautioned that trial results could shift later and that the convertible note deal might hit the share price or dilute holders. A routine Tuesday presentation won’t move things—traders are watching for bigger triggers like regulatory meetings, Phase 3 trials, or fresh data.
